Loading…
← CockpitCompetitor Analysis › 4540.T Tsumura & Co.Open in the cockpit ↗

Tsumura & Co.4540.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

Japanese maker of Kampo (traditional herbal) medicines, the market leader in prescription herbal drugs.

≈ No direct US analogue — a prescription herbal-medicine makerMomentum strong 77
Mkt cap
$1.93B
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$11.3M
20-day average traded
Fwd P/E
10.4×
forward earnings
ROIC−WACC
+0.1 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
83 days
9 Feb 2027
Close · JPY¥4,006
1D+1.0%
1W+4.4%
1M+4.9%
3M+6.8%
6M+6.0%
YTD-1.7%
1Y+11.9%
ATR %2.0%
52w lowhigh9.0% off high

What Tsumura & does

Japanese maker of Kampo (traditional herbal) medicines, the market leader in prescription herbal drugs.

Its Kampo formulations are on Japan's national health insurance drug price list, so doctors prescribe them with the cost largely reimbursed, and the government sets the price and reviews it regularly. Most herbal raw material is imported, largely from China, so ingredient supply and cost matter.

In one line: No direct US analogue — a prescription herbal-medicine maker.

Products and services

  • Kampo prescription medicines
  • Raw herbal material sourcing/processing

Customers

  • Physicians prescribing Kampo medicine
  • Patients

Where it sits in the supply chain

  • Health care
  • Pharmaceuticals
  • Kampo (herbal) prescription medicine…

What could go right

  • Aging population/chronic disease Kampo prescriptions

What could go wrong

  • Herbal raw material (mostly imported from China) cost/supply risk

Moat: wide (regulatory licence, brand, scale). Dominant share and long regulatory/insurance approval history in Japan's unique Kampo drug category.

Headquarters: Kyoto, Japan · Founded: 1893 · Employees: 4,923

Named competitors

  • Kracie Holdings private or unlisted
  • Uchida Wakanyaku (private) private or unlisted

Tsumura & at a glance

Size Tsumura & (4540.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $1.93B, the 502nd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,006 on 18 Nov 2026.

Performance Over six months the shares gained 6.0%, against -5.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 13.3% over the last twelve months (peer median +8.7%); the operating margin is 17.9% (peer median 20.9%).

Valuation It trades at 10.4× forward earnings against a peer median of 22.8× (3rd cheapest of 17).

Capital Return on invested capital runs 0.1 points above its cost of capital (5.0% WACC).

Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 20264540.T 105Peer median 93
Six months, rebased to 100: Tsumura & against the median of its 20 peers (local-currency closes).

Tsumura & financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥206B¥193B¥181B¥151B¥140B
Revenue growth—+6%+20%+8%—
Gross profit¥96.7B¥91.5B¥90.6B¥68.8B¥68.3B
EBITDA¥51.6B¥48.3B¥51.3B¥30.8B¥31.5B
Net income¥31.8B¥28.1B¥32.4B¥16.7B¥16.5B
Free cash flow-¥4.54B-¥9.16B¥6.23B-¥11.2B¥4.23B
Capital expenditure¥37.7B¥34.4B¥29.8B¥20.1B¥14.7B
Total debt¥153B¥136B¥70.8B¥80.1B¥80.0B

Quarterly statements and history in the cockpit →

Tsumura & competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-10%0%+10%+20%6002010512HRMYONESOURCEBHVNSHILPAMEDALIVUSERISPFIZER300009600211COHANCE9969009420000908DMP3004366034566037076002854540.T6-month return →1-month return →
Up and to the right = strong over both horizons. Tsumura & is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%50×100×6002010512HRMYONESOURCESHILPAMEDALIVUSERISPFIZER300009600211COHANCE99696037074540.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tsumura & is the large dot.

Tsumura & competitors and peer comparison

How Tsumura & compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tsumura & against its 20 peers (data as of 18 Nov 2026)
Measure4540.TPeer medianRank in peer set
1-month return+4.9%+0.3%8th highest of 21
6-month return+6.0%-5.5%8th highest of 21
Distance from 52-week high-9.0%-28.8%3rd highest of 21
Revenue growth (TTM)+13.3%+8.7%6th highest of 20
Operating margin17.9%20.9%10th lowest of 20
Forward P/E10.4×22.8×3rd cheapest of 17
ROIC minus cost of capital+0.1 pp+1.6 pp10th lowest of 20
EV / EBITDA8.1×17.8×3rd cheapest of 10
Net debt / EBITDA1.0×1.4×5th least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%27.9×26.3%+20.9%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
InnoCare Pharma 9969.HKHong Kong$2.01B-10%+146%35%32.2×-2.0%+341.1%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%16.9×1.7%+15.7%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%25.9×5.1%+6.4%
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%15.9×-4.7%+10.6%

Questions

Who are Tsumura &'s main competitors?
Named competitors: Kracie Holdings (private or unlisted), Uchida Wakanyaku (private) (private or unlisted). The cockpit's measured peer set (industry) also includes Jinyu Bio-Technology (600201.SS), Grand Pharmaceutical (0512.HK), Harmony Biosciences (HRMY), OneSource Specialty Pharma (ONESOURCE.NS), Biohaven (BHVN), Shilpa Medicare (SHILPAMED.NS).
Is Tsumura & expensive compared with its peers?
On forward p/e it trades at 10.4× against a peer median of 22.8×, 3rd cheapest of 17 in its peer set.
How has Tsumura & stock performed?
Over six months to 18 Nov 2026 the shares returned +6.0% against -5.5% for the median peer; over one year +11.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.